Steroid/androgen synthesis pathway and the sites of inhibition of... | Download Scientific Diagram
Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1 | Drug Metabolism & Disposition
Androgen receptor antagonism and impact on inhibitors of androgen synthesis in prostate cancer therapy - Njar - Translational Cancer Research
Frontiers | Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer | Oncology
CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents | Nature Reviews Urology
CYP17A1 - an overview | ScienceDirect Topics
CYP17A1 inhibitor - Wikipedia
CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials Cao Q, Bai P, Shi D, Liao J, Shi H, Xing Y, Chen K, Zhang X -
CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents | Nature Reviews Urology
Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer
CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials Cao Q, Bai P, Shi D, Liao J, Shi H, Xing Y, Chen K, Zhang X -
Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors | Scientific Reports
Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer – The urologists' perspective - ScienceDirect
P450 Signaling | CYP450
APExBIO - Abiraterone|Potent CYP17 inhibitor|CAS# 154229-19-3
Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases - ScienceDirect
CYP17 inhibitors for prostate cancer therapy. - Abstract - Europe PMC
CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents | Nature Reviews Urology
Steroidal CYP17 Inhibitors for Prostate Cancer Treatment: From Concept to Clinic | IntechOpen
The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature. - Abstract - Europe PMC
CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer | British Journal of Cancer
Steroidal CYP17 Inhibitors for Prostate Cancer Treatment: From Concept to Clinic | IntechOpen
